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Alzheimer’s Disease (AD) is a neurodegenerative disorder characterized by progressive
cognitive decline and dementia. Recent advances indicate that AD pathogenesis appears
more complex than its mere neuropathology. Changes in synaptic plasticity, neuronal
disarray and cell death are pathways commonly recognized as pathogenic mechanisms
of AD. It is thought that the altered metabolism of certain membrane proteins may lead to
the production of amyloid (Aβ) oligomers that are characterized by an highly toxic effect on
neurotransmission pathways, such as those mediated by Acetylcholine. The interaction of
Aβ oligomers with these neurotansmitters systems would in turn induce cell dysfunction,
neurotransmitters signaling imbalance and finally lead to the appearance of neurological
signs. In this perspective, it is still debated how and if these mechanisms may also engage
the dopaminergic system in AD. Recent experimental work revealed that the dopaminergic
system may well be involved in the occurrence of cognitive decline, often being predictive
of rapidly progressive forms of AD. However, a clear idea on the role of the dopamine
system in AD is still missing. Here we review the more recent evidences supporting
the notion that the dopaminergic dysfunction has a pathogenic role in cognitive decline
symptoms of AD.
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INTRODUCTION
Alzheimer’s disease (AD) is the most common form of human
cognitive decline and dementia. AD is highly associated with
aging and its pathological hallmarks, namely senile plaques (SP)
and neurofibrillary tangles (NFT). It has been considered for a
long time the result of an accelerated aging process of the brain
since its pathological features resemble what we might find in
aged brain (Becker et al., 2011; Ferrer, 2012). AD is currently
defined as a progressive neurodegenerative disorder character-
ized by attention deficits, associated with progressive amnesia,
apraxia, aphasia, agnosia, often associated with behavioral symp-
toms like anxiety, apathy, agitation, and in the later stages to
hallucinations and psychosis (Lowe et al., 2009). Experimental
and clinical evidences showed that AD is the consequence of
the pathologic cleavage of a membrane protein, the amyloid
precursor protein (APP), whose functions are still under study
(Nalivaeva and Turner, 2013). Amyloid hypothesis postulates
that APP undergoes impairment of physiological cleavage system
due to unknown trigger(s), producing oligomeric toxic species,
which are able to induce impairment of synaptic plasticity mech-
anisms, neuronal network disarrangement and cell death (Hardy
and Selkoe, 2002). Oligomers are physiologically produced, and
likely involved in cell signaling, and cleared either by proteolytic
systems or in balance with monomers with protective function
(Turner et al., 2003; Puzzo et al., 2008). An imbalance between
production and clearance is supposed to lead to overproduction
of oligomers, which altered stoichiometry could be responsi-
ble for cell degeneration and death (Jin et al., 2011; Puzzo and
Arancio, 2013). Oligomers induce metabolic and morphologic
changes in pyramidal neurons of the hippocampus and of the
neo-cortex. Prefrontal and cingulate cortices together with hip-
pocampus show changes since early stage of the disease and are
responsible for cognitive decline symptoms (Sperling et al., 2010).
Sub-cortical nuclei, serotonin- norepinephrine- and dopamine-
containing, constitute the monoaminergic ascending innervating
system that diffusely synapse onto hippocampal and neocorti-
cal neurons, with several modulatory effects on neuronal firing
(Trillo et al., 2013). Recent neuro-pathological studies have estab-
lished a link between morphological and functional changes
occurring in the monoaminergic ascending system, particularly
in norepinephrine and serotonin, and the pathophysiology of
AD (Simic et al., 2009; Trillo et al., 2013). The progressive
degeneration of these nuclei, that represents an early event,
deprives hippocampal and cortical neurons from their criti-
cal influence. The progressive denervation could be the cause
of cognitive decline symptoms presenting with AD. In asso-
ciation to cognitive decline symptoms about 35–40% of AD
patients present with extrapyramidal signs, supporting the idea
that dopamine (DA) containing neurons undergo degenera-
tive changes (Lopez et al., 1997). Neurons forming the nigros-
triatal pathway showed several pathologic changes like NFT,
Aβ plaques, neuropil threads, neuronal loss and also decrease
in DA content, all changes suggesting the clear involvement
of DA in the pathophysiology of cognitive decline and non-
cognitive symptoms of AD (Rudelli et al., 1984; Gibb et al.,
1989; Braak and Braak, 1990; Selden et al., 1994; Storga et al.,
1996; Burns et al., 2005). Despite that, the direct involvement
of DA in AD still remains debated (Lopez et al., 1997). Aim
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of this work is to define the possible role of DA in the course
of AD.
DOPAMINE SYSTEM ANATOMY
Dopamine (DA) containing neurons are mainly located in the
midbrain. They can be detected in A8, A9, A10 areas corre-
sponding to the retrorubral field (A8), the Substantia Nigra pars
compacta (SNc) (A9) and the Ventral Tegmental Area (VTA)
(A10). Each area projects to different brain regions, exerting dif-
ferent functions. SNc gives rise to the meso-striatal pathway,
targeting the medium spiny projection neurons of the caudate
and putamen nuclei (Lammel et al., 2011; Bolam and Pissadaki,
2012). This pathway together with the corticostriatal glutamater-
gic projections (from the sensory-motor cortex) are involved in
the control of voluntary movements. VTA instead gives rise to
the meso-cortico-limbic pathway, targeting hippocampi, cerebral
cortex and the nucleus accumbens. DA terminals together with
glutamatergic projections from amygdala, hippocampus and pre-
frontal cortex (PFC), are involved in the control of volition and
reward (Haber and Fudge, 1997; Haber and Knutson, 2010). The
A8 field represents the 4–5% of DA neurons, whose targets haven
not been fully discovered yet. In general, pathological alterations
of the meso-striatal pathway are generally associated to the devel-
opment of extrapyramidal motor deficits, while the involvement
of the meso-cortico-limbic pathway is responsible for cognitive,
behavioral signs. Both could be involved in progression of AD.
DOPAMINE SYSTEM IN ALZHEIMER’S DISEASE
Brain cell types show different sensitivity to toxic Aβ oligomers,
being cholinergic the most sensitive, followed by serotonin-ergic.
GABA-ergic cell types are less vulnerable to Aβ pathology in
comparison with the latter. DA-ergic neurons show intermediate
features, having anyhow an unclear relationship with Aβ pathol-
ogy (Kar et al., 2004). The involvement of DA in AD has been
investigated for a long time and is still under debate (Attems
et al., 2007; Portet et al., 2009; Trillo et al., 2013). DA system
undergoes several changes during physiological aging process.
In general, decreased release of DA from its terminals, reduced
DA receptor expression in particular D2 subtypes, reduced DAT
expression in caudate putamen, hippocampus and frontal cor-
tex of humans are features commonly observed in the brain
during brain aging (Volkow et al., 1994; Bäckman et al., 2010).
The association with a physiologically reduced glutamate release
from frontal and prefrontal cortices, hippocampi and amygdala
would induce further decrease of DA release, inducing hypo-
activity, gait disturbances and decline of executive functions.
The occurrence of apathy, a negative prognostic sign in both
elderly and AD, is suggested to be the consequence of the impair-
ment of DA transmission observed during normal aging as well
(Robert et al., 2010). Decline of executive functions and apathy
are predictive of “unsuccessful aging” and are considered indi-
cators of frailty among the elderly (Yates, 2002; Depp and Jeste,
2006). Similarly, in AD patients, apathy and executive dysfunc-
tion have negative prognostic value and are considered predictive
of faster cognitive decline and life shortening (Musicco et al.,
2010; Koch et al., 2013). Extrapyramidal signs like bradykine-
sia, face masking, tremors, gait disturbances, may occur early
or more commonly in the later stages of AD, particularly if the
patient is under treatment with neuroleptics (Portet et al., 2009;
Vilalta-Franch et al., 2013). In this view in both physiological
and pathological processes the appearance of DA dysfunction
represents a negative prognostic evolution. Thus, the earlier the
impairment of DA system occurs, the fastest the cognitive decline
goes. These considerations are in contrast with early neuropatho-
logical studies that found no neuronal loss but only degenerative
changes like Lewy bodies or (NFT). These findings suggest that
extrapyramidal signs (EPS) appearance could be dependent on
extra-nigral mechanisms, given that there is a lack of severe
pathology of DA system in AD (Murray et al., 1995; Burns et al.,
2005; Attems et al., 2007). Although these data are consistent
with in vivo imaging and neuropathologic studies on meso-
striatal pathways in AD and Lewy bodies dementia (DLB) patients
(Colloby et al., 2012), the involvement of nigrostriatal pathway
with Lewy bodies and alpha sinucleinopathy, generally associated
to the occurrence of DLB, has been observed in about half of
AD patients as well as 30% of aged healthy controls (Jellinger,
2004). Therefore, the presence of such pathological changes have
pathogenetic and clinical relevance to be still elucidated in cases
of DLB as well as of AD (Jellinger, 2009; Huang and Halliday,
2013). However, several recent experimental evidences renewed
interest on DA involvement in AD pathogenesis. Indeed, experi-
mental data from transgenic mice AD showed how the DA-ergic
pathology and amyloid deposition are closely related, suggest-
ing a causative role for amyloid on dopamine dysfunction (Perez
et al., 2005). Moreover, the restoration of DA transmission was
demonstrated to play a role in memory and learning in a mouse
model of AD, strengthening the central role of DA in cognitive
tasks (Ambrée et al., 2009; Guzmán-Ramos et al., 2012). This has
been recently associated to a demonstrated protective role, having
DA an anti-amyloidogenic and anti-oxidant effects in mice brain
(Himeno et al., 2011). Moreover, although the pathological sub-
strates of extrapyramidal signs remains debated, recent study on
AD with parkinsonian features showed that motor impairment
is the consequence of nigrostriatal pathology, leading authors to
conclude that prominent subcortical involvement occur in these
patients, a process apparently not related to the Braak stages
(Horvath et al., 2014). Accordingly, signs of tau pathology in
brain stem nuclei, becoming increasingly involved with AD pro-
gression has been proposed (Grinberg et al., 2009; Simic et al.,
2009; Attems et al., 2012). More details on DA transmission sys-
tem in both cortical and sub-cortical brain areas, which have
never been observed before, have been recently discovered. In par-
ticular, a markedly reduced expression of both subtypes of DA
receptors, D1-like and D2-like has been observed in prefrontal
cortex and in hippocampus of AD patients (Kemppainen et al.,
2003; Kumar and Patel, 2007). Interestingly, although the dor-
sal striatum is relatively spared in AD, its ventral homologous,
the nucleus accumbens, is highly affected. A decreased dopamine
receptor expression, particularly D2-like, a reduced expression of
Dopamine Transporter and Tyrosine Hydroxylase Enzyme were
observed in this nucleus (Rinne et al., 1986; Allard et al., 1990;
Murray et al., 1995; Joyce et al., 1997). Furthermore, recent imag-
ing studies showed atrophy of this nucleus in a cohort of late onset
AD patients, but not in the early-onset AD patients (Pievani et al.,
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2013). Electrophysiological studies performed on AD patients
showed unexpected positive effects of DA drugs on cortical neu-
rotransmission and synaptic plasticity mechanisms and also on
cognitive performances, suggesting a possible therapeutic effects
for these drugs in the treatment of AD (Martorana et al., 2009,
2013; Koch et al., 2014). All these data strengthen the hypothe-
sis of DA involvement in AD, without answering the fundamental
question: how DA dysfunction occurs?
DOPAMINE DYSFUNCTION HYPOTHESIS
Amyloid hypothesis remains the leading hypothesis to interpret
the neurotransmitters dysfunctions occurring in AD since early
phases of the disease. In this section we suggest at least two
possible pathogenetic mechanisms that might be responsible for
the DA-ergic dysfunction since early phases of the disease. Aβ
oligomers show highly toxic and deleterious effects on neuronal
arrangement and neurotransmission, and cause neuronal death
of the neocortex and hippocampi (Palop and Mucke, 2010).
In experimental models Aβ oligomers have been postulated to
induce pathological synaptic plasticity, with altered glutamate
transmission, impairment of the long term potentiation, pro-
longed and pathological long term depression, with subsequent
spine shrinkage, and activation of enzymatic pathways leading
to apoptosis and cell death (Palop and Mucke, 2010). All these
changes occur at the level of glutamatergic synapses, obeying
to the hypothesized excitotoxic hypothesis of AD. Aβ oligomers
are also able to induce multiple effects on acetylcholine neurons
transmission, impairing physiological cell metabolism, transmit-
ter synthesis and release, until cell degeneration (Kar et al.,
2004; Ferrer, 2012; Esposito et al., 2013). Beside cholinergic neu-
rons degeneration, several Aβ-mediated effects are secondary
to its binding to cholinergic receptors, particularly with nico-
tinic receptors (Schliebs and Arendt, 2011). Neuronal nicotinic
acetylcholine receptors (nAChR) are a family of ligand-gated pen-
tameric cation channels constituted by a combination of α and
β subunits (α2-6 and β2-4). The other major neuronal nAChRs
subtype contain the α7 subunit (bungarotoxin sensitive). nAChRs
can be located on the presynaptic terminal where they regulate
post-synaptic transmission and modulate pre-synaptic transmit-
ter release. Post-synaptic localization mediates depolarization of
neurons (Ni et al., 2013). The main role of nAChRs in the brain
is to regulate transmitters release and allow Ach to participate
in attention, learning and memory functions through the α4β2
and α7 receptors. The α7AChRs are located predominantly, but
not exclusively, at pre-synaptic sites of (PFC), hippocampus, tha-
lamus, serotonin-raphe nucleus and DA neurons of the VTA.
Pre-synaptic localization of these receptors increase the probabil-
ity of neurotransmitters release, while post-synaptic localization
through the intracellular Ca2+ increase activates intracellular
metabolic pathways, which are related to neuronal homeosta-
sis, synaptic plasticity, learning, and memory (Alkondon and
Albuquerque, 2002). Several lines of evidence indicate that Aβ
oligomers have the ability to bind to α7 nAChRs (Schliebs and
Arendt, 2011; Posadas et al., 2013). The high affinity interac-
tion with these receptors can cause intracellular Ca++ increase
and activation of the ERK-MAPK cascade with positive modu-
latory effects on synaptic plasticity mechanisms and functions
like memory and learning in hippocampal neurons. Conversely,
the prolonged exposure to high Aβ oligomers can reverse such a
positive effect inducing the formation of LTD and impairment
of synaptic mechanism machinery and of learning and mem-
ory. Such conflicting effects are likely dependent on concentration
and stoichiometry of the Aβ oligomers. Very low concentrations
(picomolar) are able to enhance memory and synaptic func-
tions, on the contrary higher concentrations (nanomolar) and
prolonged exposure to them can disrupt mechanisms of synap-
tic plasticity and memory functions (Puzzo and Arancio, 2013).
Since that, it is conceivable to suppose that DA dysfunction in AD,
at least in early stages, could be the consequence of Aβ peptides
production and prolonged interaction with α7 nAChRs, over-
whelming the nicotinic receptor function, and interfering with
the physiological DA functioning. Thus, prolonged exposure to
Aβ would progressively impair the physiological release of glu-
tamate and of GABA reducing the possibility of DA release in
prefrontal cortex and hippocampus, contributing to the impair-
ment of attention, memory, and executive functions. The progres-
sive decrease of glutamate release from the PFC would in turn
reduce the stimulus for DA release also in the NAcc, being respon-
sible for appearance of apathy and motor hypoactivity (Wang
et al., 2000; Posadas et al., 2013). In the later stages, following
prolonged dysfunctioning of nicotinic receptors in the SN, the
inactivation of ERK-MAPK pathways would favor cytoskeletal
tau protein hyperphosphorylation process (Wang et al., 2000)
with neuronal degeneration and cell death. The persistence of
this mechanism could be responsible for SNc neurons degener-
ation and for the appearance of extrapyramidal signs. Alternative
hypothesis come directly from recent experimental evidences on
misfolding and pathological aggregation of neuronal proteins.
Recently has been shown that Aβ oligomers could be able to
induce under pathological conditions the aggregation of other
proteins like alpha-synuclein (α-syn). Experimental evidences
showed both in vivo and in vitro that Aβ was able to interfere
with α-syn inducing conformational changes and neurodegener-
ation (Iqbal et al., 2000; Mitchell et al., 2011). In physiological
conditions soluble Aβ can be identified in the cytosolic frac-
tion, in endosomes and in endoplasmic reticulum (Starkstein
et al., 2009). Similarly, monomeric α-syn is primarily found
in the cytosolic fraction and is associated with synaptic vesci-
cles where it is supposed to play a role in neurotransmitters
release (Richard et al., 2012). Under pathological conditions, both
aggregated Aβ and α-syn might associate with membranes and
accumulate in caveolae. Hence, it is suggested that during early
phases of AD, Aβ interact with α-syn bound to membrane and
inducing the aggregation of this protein and the formation of
pentamers and hexamers with ring-like structure that associate
to membrane forming pores. These structures would form ion-
permeable channels, particularly for Ca2+ that may play a role
in the mechanisms of neurodegeneration (Van der Vlies et al.,
2009; Iqbal et al., 2013). Such interesting hypothesis that pro-
posed for DLB cases has been suggested also for AD and PD
cases though needs to be further investigated however. Therefore,
the production of pathologic Aβ would be responsible for DA-
ergic pathology and as a consequence for extrapyramidal behav-
ioral/motor deficits in early phases of AD. Such mechanism could
Frontiers in Aging Neuroscience www.frontiersin.org September 2014 | Volume 6 | Article 252 | 3
Martorana and Koch Dopamine in Alzheimer
be reasonably responsible also for rapid progression of cognitive
decline.
CLINICAL FEATURES OF DOPAMINE-DEPENDENT
SYMPTOMS
Apathy is the most common neurobehavioral symptom associ-
ated to AD. EPS are associated to AD disease progression, often
related to neuroleptic assumption, and are definitely a nega-
tive prognostic sign. Both apathy and EPS are secondary to DA
dysfunction and their appearance is a sign of disease progres-
sion for individuals with mild cognitive impairment, as well as
for AD patients (Iqbal et al., 2000; Mitchell et al., 2011). Both
clinical conditions are associated to Aβ burden, and both could
co-exist in the same individual. Although frequently described,
not all individuals with AD diagnosis may experience apathy
and EPS symptoms during their life. About half of AD patients
presents with symptoms of apathy, and one third with EPS in
early-mid stage of the disease. In the later stages of disease,
accomplice physiological aging, EPS are more clearly and eas-
ily diagnosed in almost all individuals with AD. Nowadays, Aβ
levels are easily detectable in CSF of AD individuals and cur-
rently used for diagnostic purposes. Due to its low threshold,
Aβ levels that are so useful to individuate cognitively com-
promised individuals, unfortunately cannot be used to evaluate
whether the oligomer-mediated toxicity has already reached cor-
tical and/or subcortical nuclei. Results from recent neuropatho-
logical and clinical studies pointed out the need to individuate
different subgroups of AD patients, possibly characterized by
a clinical hallmarks to obtain patients stratification for clinical
purposes (Starkstein et al., 2009; Richard et al., 2012). These
would help to better individuate patients with more prominent
cholinergic/glutamatergic deficits with respect to those presenting
with symptoms of DA dysfunction and so on. Recently pub-
lished clinical studies described features of AD patients through
their different degrees of progression. Clusters of AD diagnosed
patients were identified and characterized by different degree of
executive functions impairment, high levels of CSF tau and phos-
phorylated tau with low levels of Aβ1-42, presence of apathy,
limited or absent response to pharmacological treatment with
cholinesterase inhibitors (Van der Vlies et al., 2009; Mitchell
et al., 2011; Iqbal et al., 2013; Koch et al., 2013; Horvath et al.,
2014). Among them the presence of both apathy and very high
levels of CSF tau protein were related to more rapid progres-
sion of cognitive decline (Wallin et al., 2010; Schmidt et al.,
2011). Tau pathology is considered the hallmark of neurodegener-
ation, and it is not specific for AD. Interestingly, recent literature
showed the presence of tau related pathology in brainstem of
AD. These authors claimed that a certain degree of tau pathol-
ogy in the monoaminergic tract could represent the substrate
for more intense neurodegeneration in AD cases (Attems et al.,
2007, 2012; Simic et al., 2009; Trillo et al., 2013). This would
indicate that a subset of AD individuals could be more prone to
develop DA-deficit related symptoms. Moreover, the monoamin-
ergic tract have been shown to be able to control the physiologic
amyloid-synthesis process (Himeno et al., 2011). It is conceivable
to suppose that the progressive dysfunction and/or degeneration
of monoaminergic neurons could represent a step forward for
increased amyloid production and for amyloid-related degener-
ation of neurons.
CONCLUSIONS
Different degree of DA dysfunction can occur during any phases
of AD. The most important symptoms related to DA dysfunc-
tion are the presence of apathy and EPS. The occurrence of these
symptoms could be related to pre-existing brainstem pathology.
Their burden can vary in relation to the age of an individual
that remains the most important risk factor associated to AD. In
general, DA related symptoms appearance is related to increased
intensity of neuronal degeneration and to faster cognitive decline.
In our recent experience the use of dopaminergic drugs, in partic-
ular of the DA- D2-agonists rotigotine, showed beneficial effects
on some cognitive domains in AD patients (Koch et al., 2014).
The use of these drugs was well tolerated with no relevant behav-
ioral side effects. Future clinical trials are needed to verify the
potential therapeutic effectiveness of dopaminergic drugs in AD
patients.
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